EGFR and colorectal carcinoma: Igarashi et al. stated that miR-31-5p overexpression, in absence of mutations in KRAS, NRAS and BRAF gene, was associated with short progression-free survival in patients with CRC treated with anti-EGFR therapies, suggesting that miR-31-5p could be a prognostic biomarker for anti-EGFR therapies 60.